Back to search results

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Abroad (travel likely)RecruitingPHASE2

Conditions

HER2-negative Breast Cancer · Metastatic Breast Cancer · Metaplastic Breast Carcinoma · TNBC - Triple-Negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • National Institute of Health Clinical Center, Bethesda, Maryland, United States

    Contact: Study coordinator (Stanley Lipkowitz, Principal Investigator, MD) · lipkowis@navmed.nci.nih.gov · 240-541-4547

  • Houston Methodist Neal Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Polly Niravath, MD)

  • The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Clinton Yam, Principal Investigator, MD, MS) · TNBC-NOW@mdanderson.org · 713-792-2817
Study leads

  • Polly A Niravath, MD

    Principal Investigator

    Houston Methodist Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)